Nextech Invest’s Corvus Pharmaceuticals CRVS Stock Holding History

Nextech Invest’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.72M	Hold	450,000	–	–	0.32%	13
2026 Q1	$6.58M	Buy	+450,000	New	+$7.18M	0.46%	13

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest's CRVS Position: Q2 2026 in Review

Nextech Invest held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 450,000 shares worth $6.72M. The position accounts for 0.32% of the portfolio, ranked #13.

Nextech Invest first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Nextech Invest held 450,000 shares of Corvus Pharmaceuticals worth $6.72M as of Q2 2026.
Nextech Invest left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
Corvus Pharmaceuticals made up 0.32% of Nextech Invest's portfolio in Q2 2026, its #13 holding.
Nextech Invest first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Nextech Invest's 13F filing for Q2 2026, filed 14 Aug 2026.